Exchange: NASDAQ·Updated 07:37 PM EST

NKTX News

News
all
press releases
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow...
SeekingAlpha
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow...
SeekingAlpha
More News
Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock increased byread more...
Benzinga
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...
PR Newswire
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire
Nkarta (NASDAQ:NKTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has...
MarketBeat
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1% - Here's Why...
MarketBeat
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
Zacks
Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to...
MarketBeat

Advertisement|Remove ads.